Try the Demo today!
| SEC Filing | Insider | Company | Trade Date | Transaction | Shares | Avg. Price | Total | % Holdings | Return |
|---|---|---|---|---|---|---|---|---|---|
| 11-Mar-24 8:09 PM View:  | Garofalo Elizabeth A. Director | Xenon Pharmaceuticals Inc. (XENE) | 08-Mar-24 | Option Exercise | 3,500 | $18.56 | $64,960.00 | 100% 0 to 3.5K | |
| 11-Mar-24 8:09 PM View: | Garofalo Elizabeth A. Director | Xenon Pharmaceuticals Inc. (XENE) | 08-Mar-24 | Option Sale | 2,092 | $45.69 | $95,583.50 | (100%) 2.09K to 0 | |
| 11-Mar-24 8:09 PM View: | Garofalo Elizabeth A. Director | Xenon Pharmaceuticals Inc. (XENE) | 08-Mar-24 | Payment of Exercise | 1,408 | $46.16 | $64,993.30 | (40%) 3.5K to 2.09K | |
| 08-Mar-24 5:31 PM View: | Robin Sherrington EVP, Strategy & Innovation | Xenon Pharmaceuticals Inc. (XENE) | 07-Mar-24 | Option Exercise | 8,641 | $9.85 | $85,113.90 | 103% 8.4K to 17.04K | |
| 08-Mar-24 5:28 PM View: | Gannon Steven Director | Xenon Pharmaceuticals Inc. (XENE) | 07-Mar-24 | Private Sale | 13,000 | $46.28 | $601,615.00 | (87%) 15.0K to 2.0K | |
| 08-Mar-24 5:31 PM View: | Robin Sherrington EVP, Strategy & Innovation | Xenon Pharmaceuticals Inc. (XENE) | 07-Mar-24 | Payment of Exercise | 1,504 | $45.96 | $69,123.80 | (9%) 17.04K to 15.54K | |
| 08-Mar-24 5:31 PM View: | Robin Sherrington EVP, Strategy & Innovation | Xenon Pharmaceuticals Inc. (XENE) | 07-Mar-24 | Option Sale | 7,137 | $46.28 | $330,290.00 | (46%) 15.54K to 8.4K | |
| 02-Jan-24 4:41 PM View: | Robin Sherrington EVP, Strategy & Innovation | Xenon Pharmaceuticals Inc. (XENE) | 29-Dec-23 | Disposition (other) | 8,398 | -- | -- | (50%) 16.8K to 8.4K | |
| 20-Dec-23 5:04 PM View: | Azab Mohammad Director | Xenon Pharmaceuticals Inc. (XENE) | 19-Dec-23 | Option Exercise | 4,320 | $9.85 | $42,552.00 | 6% 69.91K to 74.22K | |
| 15-Dec-23 5:38 PM View: | Patou Gary Director | Xenon Pharmaceuticals Inc. (XENE) | 13-Dec-23 | Option Sale | 11,380 | $39.29 | $447,085.00 | (24%) 47.45K to 36.07K | |
| 15-Dec-23 5:38 PM View: | Patou Gary Director | Xenon Pharmaceuticals Inc. (XENE) | 13-Dec-23 | Payment of Exercise | 3,022 | $39.68 | $119,913.00 | (6%) 50.48K to 47.45K | |
| 15-Dec-23 5:38 PM View: | Patou Gary Director | Xenon Pharmaceuticals Inc. (XENE) | 13-Dec-23 | Option Sale | 3,022 | $41.05 | $124,053.00 | (8%) 36.07K to 33.05K | |
| 15-Dec-23 5:38 PM View: | Patou Gary Director | Xenon Pharmaceuticals Inc. (XENE) | 13-Dec-23 | Option Exercise | 14,402 | $9.55 | $137,487.00 | 40% 36.07K to 50.48K | |
| 15-Dec-23 5:38 PM View: | Patou Gary Director | Xenon Pharmaceuticals Inc. (XENE) | 13-Dec-23 | Sale | 4,576 | $41.05 | $187,845.00 | (14%) 33.05K to 28.48K | |
| 24-Aug-23 4:33 PM View: | Graham Dawn Director | Xenon Pharmaceuticals Inc. (XENE) | 24-Aug-23 | Private Sale | 25,000 | $38.70 | $967,500.00 | (50%) 50.0K to 25.0K | |
| 01-Jun-23 7:25 PM View: | Pimstone Simon N. Director | Xenon Pharmaceuticals Inc. (XENE) | 01-Jun-23 | Payment of Exercise | 22,605 | $38.53 | $870,971.00 | (37%) 60.32K to 37.71K | |
| 01-Jun-23 7:25 PM View: | Pimstone Simon N. Director | Xenon Pharmaceuticals Inc. (XENE) | 01-Jun-23 | Option Exercise | 54,318 | $16.03 | $870,856.00 | 905% 6.0K to 60.32K | |
| 01-Jun-23 7:25 PM View: | Pimstone Simon N. Director | Xenon Pharmaceuticals Inc. (XENE) | 01-Jun-23 | Option Sale | 31,713 | $38.82 | $1,231,250.00 | (84%) 37.71K to 6.0K | |
| 01-Jun-23 7:25 PM View: | Pimstone Simon N. Director | Xenon Pharmaceuticals Inc. (XENE) | 31-May-23 | Option Sale | 59,318 | $38.70 | $2,295,890.00 | (87%) 68.53K to 9.21K | |
| 01-Jun-23 7:25 PM View: | Pimstone Simon N. Director | Xenon Pharmaceuticals Inc. (XENE) | 31-May-23 | Payment of Exercise | 29,309 | $38.37 | $1,124,590.00 | (30%) 97.83K to 68.53K | |
| 01-Jun-23 7:25 PM View: | Pimstone Simon N. Director | Xenon Pharmaceuticals Inc. (XENE) | 31-May-23 | Option Exercise | 79,835 | $14.80 | $1,181,870.00 | 444% 18.0K to 97.83K | |
| 01-Jun-23 7:25 PM View: | Pimstone Simon N. Director | Xenon Pharmaceuticals Inc. (XENE) | 31-May-23 | Sale | 3,208 | $38.70 | $124,165.00 | (35%) 9.21K to 6.0K | |
| 01-Jun-23 7:25 PM View: | Pimstone Simon N. Director | Xenon Pharmaceuticals Inc. (XENE) | 30-May-23 | Sale | 7,171 | $39.28 | $281,692.00 | (28%) 25.17K to 18.0K | |
| 01-Jun-23 7:25 PM View: | Pimstone Simon N. Director | Xenon Pharmaceuticals Inc. (XENE) | 30-May-23 | Private Option Sale | 29,835 | $39.28 | $1,171,980.00 | (54%) 55.01K to 25.17K | |
| 26-May-23 7:10 PM View: | Mortimer Ian PRESIDENT & CEO Director | Xenon Pharmaceuticals Inc. (XENE) | 24-May-23 | Option Sale | 31,655 | $41.41 | $1,310,930.00 | (41%) 77.26K to 45.6K | |
| 26-May-23 7:10 PM View: | Mortimer Ian PRESIDENT & CEO Director | Xenon Pharmaceuticals Inc. (XENE) | 24-May-23 | Payment of Exercise | 12,383 | $41.84 | $518,105.00 | (14%) 89.64K to 77.26K | |
| 26-May-23 7:10 PM View: | Mortimer Ian PRESIDENT & CEO Director | Xenon Pharmaceuticals Inc. (XENE) | 24-May-23 | Option Exercise | 69,340 | $9.60 | $665,536.00 | 342% 20.3K to 89.64K | |
| 24-Mar-23 7:18 PM View: | Kenney Christopher John Chief Medical Officer | Xenon Pharmaceuticals Inc. (XENE) | 24-Mar-23 | Private Sale | 700 | $35.01 | $24,507.00 | (100%) 0.7K to 0 | |
| 09-Mar-23 6:21 PM View: | Pimstone Simon N. Director | Xenon Pharmaceuticals Inc. (XENE) | 07-Mar-23 | Payment of Exercise | 3,778 | $37.13 | $140,277.00 | (5%) 78.02K to 74.24K | |
| 09-Mar-23 6:21 PM View: | Pimstone Simon N. Director | Xenon Pharmaceuticals Inc. (XENE) | 07-Mar-23 | Option Exercise | 72,016 | $2.64 | $190,225.00 | 1200% 6.0K to 78.02K | |
| 09-Mar-23 6:21 PM View: | Pimstone Simon N. Director | Xenon Pharmaceuticals Inc. (XENE) | 07-Mar-23 | Option Sale | 19,232 | $36.98 | $711,199.00 | (26%) 74.24K to 55.01K | |
| 13-Dec-22 4:29 PM View: | Azab Mohammad Director | Xenon Pharmaceuticals Inc. (XENE) | 12-Dec-22 | Option Exercise | 3,086 | $2.68 | $8,270.48 | 5% 66.82K to 69.91K | |
| 28-Nov-22 8:41 PM View: | Patou Gary Director | Xenon Pharmaceuticals Inc. (XENE) | 25-Nov-22 | Payment of Exercise | 120 | $34.37 | $4,124.40 | (< 1%) 38.13K to 38.01K | |
| 28-Nov-22 8:41 PM View: | Patou Gary Director | Xenon Pharmaceuticals Inc. (XENE) | 25-Nov-22 | Sale | 1,937 | $34.79 | $67,390.40 | (5%) 38.01K to 36.07K | |
| 28-Nov-22 8:41 PM View: | Patou Gary Director | Xenon Pharmaceuticals Inc. (XENE) | 25-Nov-22 | Option Exercise | 2,057 | $2.68 | $5,512.76 | 6% 36.07K to 38.13K | |
| 28-Nov-22 8:41 PM View: | Patou Gary Director | Xenon Pharmaceuticals Inc. (XENE) | 23-Nov-22 | Private Option Sale | 2,057 | $34.33 | $70,609.60 | (5%) 38.13K to 36.07K | |
| 07-Sep-22 4:26 PM View: | Aulin Sherry Chief Financial Officer | Xenon Pharmaceuticals Inc. (XENE) | 02-Sep-22 | Option Sale | 15,355 | $39.57 | $607,597.00 | (100%) 15.36K to 0 | |
| 07-Sep-22 4:26 PM View: | Aulin Sherry Chief Financial Officer | Xenon Pharmaceuticals Inc. (XENE) | 02-Sep-22 | Payment of Exercise | 3,293 | $39.53 | $130,172.00 | (18%) 18.65K to 15.36K | |
| 07-Sep-22 4:26 PM View: | Aulin Sherry Chief Financial Officer | Xenon Pharmaceuticals Inc. (XENE) | 02-Sep-22 | Option Exercise | 18,648 | $6.97 | $130,061.00 | 100% 0 to 18.65K | |
| 02-Sep-22 4:27 PM View: | Robin Sherrington EVP, Strategy & Innovation | Xenon Pharmaceuticals Inc. (XENE) | 01-Sep-22 | Option Sale | 43,879 | $38.18 | $1,675,480.00 | (72%) 60.67K to 16.8K | |
| 02-Sep-22 4:27 PM View: | Robin Sherrington EVP, Strategy & Innovation | Xenon Pharmaceuticals Inc. (XENE) | 01-Sep-22 | Payment of Exercise | 6,121 | $38.81 | $237,556.00 | (9%) 66.8K to 60.67K | |
| 02-Sep-22 4:27 PM View: | Robin Sherrington EVP, Strategy & Innovation | Xenon Pharmaceuticals Inc. (XENE) | 01-Sep-22 | Option Exercise | 50,000 | $4.75 | $237,500.00 | 298% 16.8K to 66.8K | |
| 02-Sep-22 4:27 PM View: | Robin Sherrington EVP, Strategy & Innovation | Xenon Pharmaceuticals Inc. (XENE) | 31-Aug-22 | Option Sale | 21,352 | $38.57 | $823,547.00 | (56%) 38.15K to 16.8K | |
| 02-Sep-22 4:27 PM View: | Robin Sherrington EVP, Strategy & Innovation | Xenon Pharmaceuticals Inc. (XENE) | 31-Aug-22 | Payment of Exercise | 1,572 | $37.86 | $59,515.90 | (4%) 39.72K to 38.15K | |
| 02-Sep-22 4:27 PM View: | Robin Sherrington EVP, Strategy & Innovation | Xenon Pharmaceuticals Inc. (XENE) | 31-Aug-22 | Option Exercise | 22,488 | $3.13 | $70,443.00 | 131% 17.23K to 39.72K | |
| 16-Aug-22 5:31 PM View: | Pimstone Simon N. Director | Xenon Pharmaceuticals Inc. (XENE) | 16-Aug-22 | Sale | 52,058 | $38.51 | $2,004,900.00 | (90%) 58.06K to 6.0K | |
| 16-Aug-22 5:31 PM View: | Pimstone Simon N. Director | Xenon Pharmaceuticals Inc. (XENE) | 15-Aug-22 | Sale | 33,942 | $37.76 | $1,281,650.00 | (37%) 92.0K to 58.06K | |
| 16-Aug-22 5:36 PM View: | Empfield James R. EVP, Drug Discovery | Xenon Pharmaceuticals Inc. (XENE) | 12-Aug-22 | Payment of Exercise | 7,257 | $38.02 | $275,911.00 | (10%) 75.0K to 67.74K | |
| 16-Aug-22 5:36 PM View: | Empfield James R. EVP, Drug Discovery | Xenon Pharmaceuticals Inc. (XENE) | 12-Aug-22 | Option Exercise | 65,000 | $4.24 | $275,750.00 | 650% 10.0K to 75.0K | |
| 16-Aug-22 5:36 PM View: | Empfield James R. EVP, Drug Discovery | Xenon Pharmaceuticals Inc. (XENE) | 12-Aug-22 | Option Sale | 57,743 | $38.31 | $2,211,980.00 | (85%) 67.74K to 10.0K |
